Intel stock extends gains after report of possible U.S. government stake
Investing.com -- Jenoptik AG reported weak second quarter results and now expects its 2025 performance to be at the lower end of its previously announced guidance range.
The company posted Q2 sales of €255 million, a 10.5% year-over-year decline and 2% below consensus estimates of €260 million.
The drop was primarily driven by weakness in the Semiconductor & Advanced Manufacturing business, which fell 15% in the quarter.
While Jenoptik achieved revenue growth in the Americas, sales in Germany, Europe, and Asia/Pacific regions failed to reach last year’s levels.
Q2 EBITDA came in at €42.6 million, down 25.2% from the same period last year, with margins declining to 16.7% compared to 20.0% in Q2 2024. Despite the decline, this figure beat consensus expectations of €45.6 million by 7%.
Jenoptik now expects its full-year 2025 revenue to fall within the lower half of its previously communicated forecast range of plus or minus 5% relative to 2024’s €1,116 million.
Similarly, the EBITDA margin is projected to align with the lower half of the earlier forecast range of 18.0-21.0%, compared to 19.9% in 2024.
The company maintains its expectation for a recovery in demand during the second half of the year, particularly in the semiconductor equipment sector.
However, this outlook faces increased risk due to existing and potential additional trade barriers.
Order intake improved significantly in Q2 to €268.1 million compared to Q1’s €204.6 million, though the first-half total of €472.7 million remained below the prior year’s level of €524.4 million.
Jenoptik also announced that the planned sale of Prodomax is no longer feasible within the current strategic timeframe, which extends through the end of 2025.
This decision comes amid ongoing challenges in the North American automotive sector, investment restraint, and continued uncertainty surrounding tariffs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.